{
    "name": "neostigmine",
    "comment": "Rx",
    "other_names": [
        "Prostigmin",
        "Bloxiverz"
    ],
    "classes": [
        "Acetylcholinesterase Inhibitors",
        "Peripheral"
    ],
    "source": "https://reference.medscape.com/drug/prostigmin-bloxiverz-neostigine-343064",
    "pregnancy": {
        "common": [
            "There are no adequate or well-controlled studies in pregnant women; not known whether neostigmine can cause fetal harm or affect reproductive capacity; should administer only if clearly needed",
            "Anticholinesterase drugs, including neostigmine, may cause uterine irritability and induce premature labor when administered to pregnant women near term"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "No adverse effects were noted in rats or rabbits treated with human equivalent doses of neostigmine methylsulfate doses up to 8.1 and 13 mcg/kg/day, respectively, during organogenesis (0.1 to 0.2 times the maximum recommended human dose of 5 mg/60 kg person/day based on body surface area comparisons)"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "The drug has not been studied in lactating women; not known whether neostigmine methylsulfate is present in human milk, or has effects on milk production or breastfed child; the developmental and health benefits of breastfeeding should be considered along with motherâ€™s need for therapy and any potential adverse effects on breastfed child from drug or from underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity, previous history of reaction to bromides",
                "Peritonitis or mechanical GI or urinary tract obstruction"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "To lessen risk of bradycardia, administer glycopyrrolate or atropine sulfate prior to therapy",
                "Caution in epilepsy, bronchial asthma, bradycardia, recent coronary occlusion, vagotonia, hyperthyroidism, cardiac arrhythmias, peptic ulcer",
                "In patients with certain cardiovascular conditions such as coronary artery disease, cardiac arrhythmias or recent acute coronary syndrome, risk of blood pressure and heart rate complications may be increased; risk of these complications may also be increased in patients with myasthenia gravis; standard antagonism with anticholinergics (eg, atropine) is generally successful to mitigate risk of cardiovascular complications",
                "Neonates; because of self-limiting nature of myasthenia gravis, reduce daily dosage gradually released until drug can be withdrawn",
                "Avoid large doses in situations where there might be an increased absorption rate from the intestinal tract; caution when coadministered with anticholinergic drugs because of decreased GI motility",
                "Differentiate between myasthenic crisis and cholinergic crisis caused by overdosage of neostigmine; both conditions result in extreme muscle weakness but require radically different treatment",
                "Large doses administered when neuromuscular blockade is minimal can produce neuromuscular dysfunction; the dose should be reduced if recovery from neuromuscular blockade is nearly complete",
                "Anticholinesterase insensitivity can develop",
                "If excess cholinergic symptoms develop, discontinue therapy",
                "Atropine and epinephrine must be available to treat a hypersensitivity reaction",
                "Not recomended for use in patients with vagotonia",
                "May prolong the phase 1 block of depolarizing muscle relaxants"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "ponesimod",
            "description": {
                "common": "ponesimod, neostigmine.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Consult cardiologist if considering treatment. Coadministration of ponesimod with drugs that decrease HR may have additive effects on decreasing HR and should generally not be initiated in these patients."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "triamcinolone acetonide injectable suspension",
            "description": {
                "common": "triamcinolone acetonide injectable suspension, neostigmine. unspecified interaction mechanism. Avoid or Use Alternate Drug. Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. If possible, withdraw anticholinesterase agents at least 24 hours before initiating corticosteroid therapy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aclidinium",
            "description": {
                "common": "neostigmine increases and aclidinium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amifampridine",
            "description": {
                "common": "amifampridine and neostigmine both increase  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amitriptyline",
            "description": {
                "common": "neostigmine increases and amitriptyline decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amoxapine",
            "description": {
                "common": "neostigmine increases and amoxapine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "anticholinergic/sedative combos",
            "description": {
                "common": "neostigmine increases and anticholinergic/sedative combos decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atracurium",
            "description": {
                "common": "neostigmine increases and atracurium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atropine",
            "description": {
                "common": "neostigmine increases and atropine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atropine IV/IM",
            "description": {
                "common": "neostigmine increases and atropine IV/IM decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.  ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "belladonna alkaloids",
            "description": {
                "common": "neostigmine increases and belladonna alkaloids decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "belladonna and opium",
            "description": {
                "common": "neostigmine increases and belladonna and opium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bethanechol",
            "description": {
                "common": "bethanechol and neostigmine both increase  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carbachol",
            "description": {
                "common": "carbachol and neostigmine both increase  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cevimeline",
            "description": {
                "common": "cevimeline and neostigmine both increase  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cisatracurium",
            "description": {
                "common": "neostigmine increases and cisatracurium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clomipramine",
            "description": {
                "common": "neostigmine increases and clomipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyclizine",
            "description": {
                "common": "neostigmine increases and cyclizine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyclobenzaprine",
            "description": {
                "common": "neostigmine increases and cyclobenzaprine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "darifenacin",
            "description": {
                "common": "neostigmine increases and darifenacin decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dicyclomine",
            "description": {
                "common": "neostigmine increases and dicyclomine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diphenhydramine",
            "description": {
                "common": "neostigmine increases and diphenhydramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "donepezil",
            "description": {
                "common": "donepezil and neostigmine both increase  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dosulepin",
            "description": {
                "common": "neostigmine increases and dosulepin decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "doxepin",
            "description": {
                "common": "neostigmine increases and doxepin decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "echothiophate iodide",
            "description": {
                "common": "echothiophate iodide and neostigmine both increase  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fesoterodine",
            "description": {
                "common": "neostigmine increases and fesoterodine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "flavoxate",
            "description": {
                "common": "neostigmine increases and flavoxate decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "galantamine",
            "description": {
                "common": "galantamine and neostigmine both increase  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glycopyrrolate",
            "description": {
                "common": "neostigmine increases and glycopyrrolate decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glycopyrrolate inhaled",
            "description": {
                "common": "neostigmine increases and glycopyrrolate inhaled decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "henbane",
            "description": {
                "common": "neostigmine increases and henbane decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "homatropine",
            "description": {
                "common": "neostigmine increases and homatropine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "huperzine A",
            "description": {
                "common": "huperzine A and neostigmine both increase  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hyoscyamine",
            "description": {
                "common": "neostigmine increases and hyoscyamine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hyoscyamine spray",
            "description": {
                "common": "neostigmine increases and hyoscyamine spray decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.  ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "imipramine",
            "description": {
                "common": "neostigmine increases and imipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ipratropium",
            "description": {
                "common": "neostigmine increases and ipratropium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lofepramine",
            "description": {
                "common": "neostigmine increases and lofepramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "maprotiline",
            "description": {
                "common": "neostigmine increases and maprotiline decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "meclizine",
            "description": {
                "common": "neostigmine increases and meclizine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methscopolamine",
            "description": {
                "common": "neostigmine increases and methscopolamine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nortriptyline",
            "description": {
                "common": "neostigmine increases and nortriptyline decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "onabotulinumtoxinA",
            "description": {
                "common": "neostigmine increases and onabotulinumtoxinA decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "orphenadrine",
            "description": {
                "common": "neostigmine increases and orphenadrine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxybutynin",
            "description": {
                "common": "neostigmine increases and oxybutynin decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxybutynin topical",
            "description": {
                "common": "neostigmine increases and oxybutynin topical decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxybutynin transdermal",
            "description": {
                "common": "neostigmine increases and oxybutynin transdermal decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pancuronium",
            "description": {
                "common": "neostigmine increases and pancuronium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "physostigmine",
            "description": {
                "common": "neostigmine and physostigmine both increase  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pilocarpine",
            "description": {
                "common": "neostigmine and pilocarpine both increase  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pralidoxime",
            "description": {
                "common": "neostigmine increases and pralidoxime decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "propantheline",
            "description": {
                "common": "neostigmine increases and propantheline decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "protriptyline",
            "description": {
                "common": "neostigmine increases and protriptyline decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pyridostigmine",
            "description": {
                "common": "neostigmine and pyridostigmine both increase  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rapacuronium",
            "description": {
                "common": "neostigmine increases and rapacuronium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rivastigmine",
            "description": {
                "common": "neostigmine and rivastigmine both increase  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rocuronium",
            "description": {
                "common": "neostigmine increases and rocuronium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "scopolamine",
            "description": {
                "common": "neostigmine increases and scopolamine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "solifenacin",
            "description": {
                "common": "neostigmine increases and solifenacin decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "succinylcholine",
            "description": {
                "common": "neostigmine and succinylcholine both increase  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tiotropium",
            "description": {
                "common": "neostigmine increases and tiotropium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tolterodine",
            "description": {
                "common": "neostigmine increases and tolterodine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trimipramine",
            "description": {
                "common": "neostigmine increases and trimipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trospium chloride",
            "description": {
                "common": "neostigmine increases and trospium chloride decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "umeclidinium bromide",
            "description": {
                "common": "neostigmine increases and umeclidinium bromide decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor. Monitor when umeclidinium bromide is coadministered with cholinergic agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vecuronium",
            "description": {
                "common": "neostigmine increases and vecuronium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "acebutolol",
            "description": {
                "common": "acebutolol, neostigmine.\nEither increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive bradycardia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "atenolol",
            "description": {
                "common": "atenolol, neostigmine.\nEither increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive bradycardia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "betaxolol",
            "description": {
                "common": "betaxolol, neostigmine.\nEither increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive bradycardia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "bisoprolol",
            "description": {
                "common": "bisoprolol, neostigmine.\nEither increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive bradycardia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "carvedilol",
            "description": {
                "common": "carvedilol, neostigmine.\nEither increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive bradycardia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "celiprolol",
            "description": {
                "common": "celiprolol, neostigmine.\nEither increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive bradycardia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "desipramine",
            "description": {
                "common": "neostigmine increases and desipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "donepezil",
            "description": {
                "common": "donepezil increases effects of neostigmine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "esmolol",
            "description": {
                "common": "esmolol, neostigmine.\nEither increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive bradycardia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "galantamine",
            "description": {
                "common": "galantamine increases effects of neostigmine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "labetalol",
            "description": {
                "common": "labetalol, neostigmine.\nEither increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive bradycardia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "metoprolol",
            "description": {
                "common": "metoprolol, neostigmine.\nEither increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive bradycardia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "nadolol",
            "description": {
                "common": "nadolol, neostigmine.\nEither increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive bradycardia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "nebivolol",
            "description": {
                "common": "nebivolol, neostigmine.\nEither increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive bradycardia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "pantothenic acid",
            "description": {
                "common": "pantothenic acid, neostigmine.\nEither increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "penbutolol",
            "description": {
                "common": "penbutolol, neostigmine.\nEither increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive bradycardia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "pindolol",
            "description": {
                "common": "pindolol, neostigmine.\nEither increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive bradycardia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "procainamide",
            "description": {
                "common": "procainamide decreases effects of neostigmine by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "propranolol",
            "description": {
                "common": "propranolol, neostigmine.\nEither increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive bradycardia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "sotalol",
            "description": {
                "common": "sotalol, neostigmine.\nEither increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive bradycardia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "timolol",
            "description": {
                "common": "timolol, neostigmine.\nEither increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive bradycardia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "trazodone",
            "description": {
                "common": "neostigmine increases and trazodone decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Allergic",
            "percent": null
        },
        {
            "name": "Allergic reactions and anaphylaxis",
            "percent": null
        },
        {
            "name": "Neurologic",
            "percent": null
        },
        {
            "name": "Dizziness",
            "percent": null
        },
        {
            "name": "convulsions",
            "percent": null
        },
        {
            "name": "loss of consciousness",
            "percent": null
        },
        {
            "name": "drowsiness",
            "percent": null
        },
        {
            "name": "headache",
            "percent": null
        },
        {
            "name": "dysarthria",
            "percent": null
        },
        {
            "name": "miosis and visual changes",
            "percent": null
        },
        {
            "name": "Cardiovascular",
            "percent": null
        },
        {
            "name": "Cardiac arrhythmias",
            "percent": null
        },
        {
            "name": "including bradycardia",
            "percent": null
        },
        {
            "name": "tachycardia",
            "percent": null
        },
        {
            "name": "A",
            "percent": null
        },
        {
            "name": "V block and nodal rhythm",
            "percent": null
        },
        {
            "name": "and nonspecific EKG changes have been reported",
            "percent": null
        },
        {
            "name": "as well as cardiac arrest",
            "percent": null
        },
        {
            "name": "syncope and hypotension",
            "percent": null
        },
        {
            "name": "predominantly with parenteral dosage form",
            "percent": null
        },
        {
            "name": "Respiratory",
            "percent": null
        },
        {
            "name": "Increased oral",
            "percent": null
        },
        {
            "name": "pharyngeal and bronchial secretions",
            "percent": null
        },
        {
            "name": "and dyspnea",
            "percent": null
        },
        {
            "name": "respiratory depression",
            "percent": null
        },
        {
            "name": "respiratory arrest and bronchospasm have been reported following the use of the injectable form",
            "percent": null
        },
        {
            "name": "Dermatologic",
            "percent": null
        },
        {
            "name": "Rash and urticaria",
            "percent": null
        },
        {
            "name": "Gastrointestinal",
            "percent": null
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "emesis",
            "percent": null
        },
        {
            "name": "flatulence",
            "percent": null
        },
        {
            "name": "and increased peristalsis and salivation",
            "percent": null
        },
        {
            "name": "Genitourinary",
            "percent": null
        },
        {
            "name": "Urinary frequency",
            "percent": null
        },
        {
            "name": "Musculoskeletal",
            "percent": null
        },
        {
            "name": "Muscle cramps and spasms",
            "percent": null
        },
        {
            "name": "arthralgia",
            "percent": null
        },
        {
            "name": "Miscellaneous",
            "percent": null
        },
        {
            "name": "Diaphoresis",
            "percent": null
        },
        {
            "name": "flushing and weakness",
            "percent": null
        }
    ]
}